RxDoctor Payments Data

Stuart Horowitz, DO

Family Medicine · Massapequa, NYNPI 1972661155

Payments from drug & device makers

$9,739in general payments, 2019–2025

Across 525 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Phathom Pharmaceuticals, Inc.$924
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$600
  • Novo Nordisk$469
  • Arbor Pharmaceuticals, Inc.$456
  • GSK$443
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,739 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$812,580
Medicare patients
459
Services billed
22,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$56,278
XareltoRivaroxaban35$53,558
OzempicSemaglutide29$26,503
MounjaroTirzepatide20$26,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,495
Pitavastatin Calcium64$18,164
Breo ElliptaFluticasone/Vilanterol24$15,203
LivaloPitavastatin Calcium20$14,527
Repatha SureclickEvolocumab20$11,844
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,177
Metoprolol Succinate540$8,160
EdarbyclorAzilsartan Med/Chlorthalidone11$7,566
SynthroidLevothyroxine Sodium43$4,239
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide255$4,115
Rosuvastatin Calcium283$3,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$282$56,27852 claims
Johnson & JohnsonXarelto$391$53,55835 claims
GSKTrelegy Ellipta, Breo Ellipta$443$39,69845 claims
Novo NordiskOzempic$469$26,50329 claims
Lilly USA, LLCMounjaro$170$26,20220 claims
Kowa Pharmaceuticals America, Inc.Livalo$288$14,52720 claims
AstraZenecaBreztri Aerosphere$407$11,17711 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$456$7,56611 claims
AbbVieSynthroid$2,467$4,23943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →